REGISTERED COMPANY NUMBER: CE018092 (England and Wales) REGISTERED CHARITY NUMBER: 231708
Report of the Trustees and Financial Statements for the Year Ended 31 October 2025 for The Thalidomide Society Lewis Smith & Co. Chartered Certified Accountants The Old Doctor's House 74 Grange Road Dudley West Midlands DY1 2AW
The Thalidomide Society
Contents of the Financial Statements for the Year Ended 31 October 2025
----- Start of picture text -----
Page
Report of the Trustees 1 to 6
Independent Examiner's Report 7
Statement of Financial Activities 8
Balance Sheet 9
Notes to the Financial Statements 10 to 14
Detailed Statement of Financial Activities 15 to 16
Official Signed Copy
----- End of picture text -----
The Thalidomide Society
Report of the Trustees for the Year Ended 31 October 2025
The trustees present their report with the financial statements of the charity for the year ended 31 October 2025. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).
CHAIR'S STATEMENT
As Chair, I am pleased to present my year-end report, offering an overview of our achievements, challenges, and future aspirations.
period of significant progress and adaptation. Our team has forward and shared their experiences, many thanks go to Craig Millward, Dignity & Independence is our new project which is up and impact to support and help people move towards a place where they are you to Geraldine Freeman, Sukeshi Thakker and Eddie Freeman for their handbook is now complete, a tremendous amount of work was put in continued by Julie, Roz Hepple and me to ensure we have the we must also acknowledge the challenges encountered, particularly resource constraints that require careful navigation. Nevertheless, the priorities include building on our current momentum, investing in professional
The past year has been a period of significant progress and adaptation. Our team has demonstrated resilience, innovation, and a steadfast commitment to our shared goals, even in the face of an ever-changing environment.
Key Achievements
-
Oral History - We have begun the interviews with the siblings of our community, and I would like to thank the brothers and sisters who have come forward and shared their experiences, many thanks go to Craig Millward, Fred Dove and Carolyne De-Forge for continuing to interview and use those wonderful skills you acquired.
-
Personal Support - Maintaining our Dignity & Independence is our new project which is up and running and our first webinars have had the desired impact to support and help people move towards a place where they are comfortable in requesting support. Thank you to Geraldine Freeman, Sukeshi Thakker and Eddie Freeman for their hard work and insight in making this project a continuing success.
-
We have relaunched our magazine The Independence and are now working with an excellent graphic designer, who is working closely with both Julie Dixon and Heather Trueman. We will be producing three Newsletters each year, so it's your opportunity to share with us all your successes and experiences.
-
The updated Governance handbook is now complete, a tremendous amount of work was put in previously by Mikey Argy and Julie Dixon, and continued by Julie, Roz Hepple and me to ensure we have the appropriate policies and procedures in place to ensure the Society continues to be up to date, legal and in line with best practice.
Challenges Faced
While celebrating our successes, we must also acknowledge the challenges encountered, particularly market volatility, regulatory changes, and resource constraints that require careful navigation. Nevertheless, the dedication and professionalism of our trustees and staff have enabled us to overcome any difficulties.
Looking Ahead
Looking to the future, our priorities include building on our current momentum, investing in professional development. We remain committed to transparency, accountability, and the well-being of our staff and community
Appreciation
I wish to thank all members of the team, and give a warm welcome to Heather Trueman who will be working alongside Julie and our trustees. I very much hope you too will give a warm welcome to her. Together, we are well-positioned to meet the opportunities and challenges that lie ahead.
On behalf of the Board and myself, I look forward to another successful year.
Mandy De La Mare Chair
Page 1
The Thalidomide Society
Report of the Trustees for the Year Ended 31 October 2025
OBJECTIVES AND ACTIVITIES
Our Objectives
To assist in the relief of persons with impairments attributable to the effects of the drug known as thalidomide and other persons with similar impairments by:
-
Providing such persons, their families, and carers with opportunities to meet each other either in person or via social media, at events and meetings organised by the Society.
-
Providing support and information to such persons, their families, and carers.
-
To advance the education of the public in the subject of the history of thalidomide by collecting, collating, archiving, and preserving documents relating to the history of thalidomide and by undertaking or assisting in the undertaking of educational and research projects concerning the effects of thalidomide and work of the Society and by publishing the useful results of such educational and research projects.
undertaking of educational and research projects concerning the effects of thalidomide and work of the Society and by publishing the useful results of such educational and research projects. In setting objectives and planning for activities the trustees have given due consideration to general guidance published by the Charity commission relating to public benefit including the guidance 'Public benefit: running a charity (PB2).
Page 2
The Thalidomide Society
Report of the Trustees for the Year Ended 31 October 2025
OBJECTIVES AND ACTIVITIES
Significant activities
The digital files for the Oral History Parent Project are now with the British Library. With copyright and ownership of the project being jointly held by the Thalidomide Society and the British Library. There is still no fixed date for when the Oral History project will become live at the British Library, although the digitisation has begun and they are hopeful it will be late 2026. The sibling's part of the project is now forging ahead and many thanks to Craig Millward, Fred Dove and Carolyn De-Forge for their hard work and dedication in ensuring this project will be completed in 2026.
We launched our new project Personal Support - Maintaining our Dignity & Independence and thanks to Geraldine Freeman, Sukeshi Thakker and Eddie Freeman for leading on this project. We have already held one webinar and launched a help sheet relating to it. There is lots to do and there has been no shying away from difficult subjects. We look forward to the coming year and seeing useful and satisfying outcomes. With more useful webinars, helpful sheets and support available.
and Eddie Freeman for leading on this project. We have already held it. There is lots to do and there has been no shying away from difficult year and seeing useful and satisfying outcomes. With more useful webinars, was held at St Georges Park, mainly due to them having a larger We also gave the opportunity for members to attend via Zoom. However, in recognition that not all members are on Facebook, History Day on thalidomide and their enthusiasm for understanding yearly AGM/Conference outcomes, reproduce good news stories, Lottery is an opportunity for people to donate to the Society, and this a great opportunity to perhaps get a little gift back via our Lottery, and are delighted to welcome Heather Trueman to our team. Heather, who like Julie
Our yearly AGM/Conference was held at St Georges Park, mainly due to them having a larger number of accessible rooms. It was an enjoyable event with good feedback from those attending. Giving opportunities for members to meet up with old and new friends. We also gave the opportunity for members to attend via Zoom. However, the 2026 AGM/Conference will be held at Burleigh Court, Loughborough.
Our closed Facebook page is well used with over 340 members it is a great place with opportunities to share and gleam information with other members. However, in recognition that not all members are on Facebook, interesting and insightful information is now being shared in the Newsletters (with names removed)
We continue to receive many inquiries, particularly from 8th and 9th graders from the USA, these young people chose to do their project for National History Day on thalidomide and their enthusiasm for understanding and knowledge is commendable.
Presently our key areas of support are: - Information giving. - Signposting to other services.
This year we have relaunched our newsletter, The Independence, we are working with an experienced graphic designer, Genette Bodsworth and we thank her for her input and dedication in working to understand our needs, in the newsletter we inform members of the yearly AGM/Conference outcomes, reproduce good news stories, remind people of initiatives, such as our Lottery, and how members of the Society can get involved with the organisation. There will now be three newsletters each year.
Our Thalidomide Society Lottery is an opportunity for people to donate to the Society, and this fund raising goes towards our projects. It is also a great opportunity to perhaps get a little gift back via our Lottery, and we thank Marie Pearce for her continued support in running the lottery on behalf of the Society.
This year the Board reflected on the amount of new work that the team are doing, and it was decided to employ a second person to take on more admin. We are delighted to welcome Heather Trueman to our team. Heather, who like Julie has vast charity experience and will be a great asset to our team.
The Trustee handbook has been updated it was a big job with new policies and procedures either having to be created or updated. This will be available for all members to see in the members area of the updated website.
ACHIEVEMENTS AND PERFORMANCE
Investment Policy and Performance
At the year end the balance of the Society's investment portfolio was valued at £395,573 (2024 - £386,714) and generated income during the year of £13,648 (2024 - £15,036). The Finance Committee actively monitors these investments throughout the year.
Page 3
The Thalidomide Society
Report of the Trustees for the Year Ended 31 October 2025
FINANCIAL REVIEW
Financial position
Total income for the year was £32,069 (2024 - £48,919). Expenditure for the year (excluding the investment movements) was £76,539 (2024 - £72,109). The total funds of the charity at the year-end were £435,665 (2024 - £434,221). This consisted of unrestricted funds of £417,689 (2024 - £415,953) and restricted funds of £17,976 (2024 - £18,268).
Restricted Funds
The restricted funds are accounted for separately. These funds are generated from several sources and are restricted for specific projects. These are:
the Society's raffle and auctions at a previous AGM, as well as from £96,935 of Heritage Lottery funding for Thalidomide funds will be used solely for this project. The final tranche of funding was received are used to support the Society's Parents' Oral History Project. fund an interview with a thalidomide survivor or someone involved in of its unrestricted funds from its investment portfolio and uses this Funds, all reserves available for use by the Society are unrestricted and can its charitable aims. The Trustees are aware the Society depends upon the activities and recognise the need to source other income to embark on any savings in our expenses and manage risk appropriately. Our procedures good practices in reducing and minimising risk. We will maintain our For this reason, they continue to adopt the going concern basis in
Support for Srey Hang
Funds were generated from the Society's raffle and auctions at a previous AGM, as well as from occasional separate private donations and bequests.
Oral History Project Thalidomide Stories
In July 2018 the Society was granted £96,935 of Heritage Lottery funding for Thalidomide Stories: An Oral History of Thalidomide Survivors. The funds will be used solely for this project. The final tranche of funding was received during the 2024 financial year and the project has been completed.
Oral History Project
Parents' Oral History Funds generated from private bequests, net receipts from the Thalidomide Society Lottery, specific gifts from members and donations are used to support the Society's Parents' Oral History Project. Occasionally funds here too may be used to fund an interview with a thalidomide survivor or someone involved in the thalidomide community when it is needed for a specific talk or presentation on behalf of the Society.
Unrestricted Funds
The Society generates most of its unrestricted funds from its investment portfolio and uses this income to cover charitable activities and governance costs.
Reserves policy
Apart from the Restricted Funds, all reserves available for use by the Society are unrestricted and can be used for the Society in accordance with its charitable aims. The Trustees are aware the Society depends upon the income from its investments to fund its core activities and recognise the need to source other income to embark on any major projects. We will continue to make savings in our expenses and manage risk appropriately. Our procedures and policies are updated regularly and reflect good practices in reducing and minimising risk. We will maintain our reserves policy, reflecting adequate levels or working capital required to meet the legal responsibilities of the charity.
Going concern
After making appropriate enquires, the trustees expect the charity to have adequate resources to continue its operational existence in the near future. For this reason, they continue to adopt the going concern basis in preparing financial statements.
PLANS FOR THE FUTURE
Future Development
Our website has been revamped and will be launched in late 2025, we recognise this is an essential window to people across the UK and further afield. We hope to develop some online friendship meetings and develop webinars relating to member needs and interests. We will be developing a further new project that will help members to consider volunteering their time to deliver talks to their local communities about The Thalidomide Society and their story, ensuring our legacy is maintained.
STRUCTURE, GOVERNANCE AND MANAGEMENT
Constitution
The Thalidomide Society is a registered incorporated charity. This report and the financial statement have been prepared following the policies set out in the Constitution adopted in 2018.
The charity is controlled by its governing document, a CIO Association conversion dated 4 July 2019.
Page 4
The Thalidomide Society
Report of the Trustees for the Year Ended 31 October 2025
STRUCTURE, GOVERNANCE AND MANAGEMENT Method of appointment or election of trustees
Charity management is the responsibility of the trustees elected or co-opted under the terms of the Constitution. The Board now meets at least six times annually to regularly review strategy, budget, and performance. All trustees give their time voluntarily and receive no benefits from the charity. Potential conflicts of Interest are stated at the start of each meeting, ensuring transparency is maintained. All trustees receive relevant documentation. Trustees are encouraged to attend inexpensive and valid training courses as they arise.
Organisational structure and decision-making
The Board of Trustees is the overarching charity governors with delegated authority for the day-to-day all charity matters falling to the appointed Operations Manager with assistance from the newly Administrator. Our Trustee Board members oversee the charity's strategic direction and legal responsibilities. We look to appoint trustees that will enhance the Boards knowledge and enrich the charity. We Operations Manager and one part-time Assistant Administrator. With trustees sitting on selected sub-committees relating to Finance, Governance and Events. With one trustee being voted to line manage staff members. Risk management The trustees have a duty to identify and review the risks to which the charity is exposed and to controls are in place to provide reasonable assurance against fraud and error. REFERENCE AND ADMINISTRATIVE DETAILS Registered Company number CE018092 (England and Wales) Registered Charity number 231708 Registered office The Old Doctor's House 74 Grange Road Dudley West Midlands DY1 2AW Trustees M Argy Resigned 26/04/25 M de la Mare Chair G Freeman S Gooding R Hepple M Hogg D Mansell Treasurer D Tickell S Thakkar Resigned 09/12/25 E Freeman Appointed 26/04/25 E Hulme Appointed 26/04/25
The Board of Trustees is the overarching charity governors with delegated authority for the day-to-day management of all charity matters falling to the appointed Operations Manager with assistance from the newly appointed Assistant Administrator. Our Trustee Board members oversee the charity's strategic direction and legal responsibilities.
We look to appoint trustees that will enhance the Boards knowledge and enrich the charity. We employ one part-time Operations Manager and one part-time Assistant Administrator. With trustees sitting on selected sub-committees relating to Finance, Governance and Events. With one trustee being voted to line manage staff members.
The trustees have a duty to identify and review the risks to which the charity is exposed and to ensure appropriate controls are in place to provide reasonable assurance against fraud and error.
The following people are not trustees of the charity but hold the following positions:
Name Position J Dixon Operations Manager
Page 5
The Thalidomide Society
Report of the Trustees for the Year Ended 31 October 2025
REFERENCE AND ADMINISTRATIVE DETAILS Independent Examiner
Lewis Smith & Co. Chartered Certified Accountants The Old Doctor's House 74 Grange Road Dudley West Midlands DY1 2AW
the directors of The Thalidomide Society for the purposes of company law) the Trustees and the financial statements in accordance with applicable trustees to prepare financial statements for each financial year. Under that financial statements in accordance with United Kingdom Generally the financial statements unless they are of affairs of the charitable company and of the incoming resources and on the going concern basis unless it is inappropriate to presume charitable company and to enable them to ensure that the in accordance with the special provisions of Part 15 of the
STATEMENT OF TRUSTEES' RESPONSIBILITIES
The trustees (who are also the directors of The Thalidomide Society for the purposes of company law) are responsible for preparing the Report of the Trustees and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).
Company law requires the trustees to prepare financial statements for each financial year. Under that law, the trustees have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law).
Under company law the trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing those financial statements, the trustees are required to
-
select suitable accounting policies and then apply them consistently;
-
observe the methods and principles in the Charities SORP;
-
make judgements and estimates that are reasonable and prudent;
-
prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.
The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charitable company and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
This report has been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.
Approved by order of the board of trustees on ............................................. and signed on its behalf by:
........................................................................
Mr D Mansell - Trustee
Page 6
Independent Examiner's Report to the Trustees of The Thalidomide Society
Independent examiner's report to the trustees of The Thalidomide Society ('the Company')
I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 October 2025.
Responsibilities and basis of report
As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').
Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under Section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under Section 145(5) (b) of the 2011 Act.
I confirm that no matters have come to my attention in comply with the accounting requirements of Section 396 of the 2006 Act not been prepared in accordance with the methods and principles of
Independent examiner's statement
I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:
-
accounting records were not kept in respect of the Company as required by Section 386 of the 2006 Act; or 2. the accounts do not accord with those records; or
-
the accounts do not comply with the accounting requirements of Section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
-
the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).
I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.
Mr Craig Alan Beale FCCA
Lewis Smith & Co. Chartered Certified Accountants The Old Doctor's House 74 Grange Road Dudley West Midlands DY1 2AW
Date: .............................................
Page 7
The Thalidomide Society
Statement of Financial Activities for the Year Ended 31 October 2025
| Official Signe Unrestricted fund Notes £ INCOME AND ENDOWMENTS FROM Donations and legacies - Charitable activities Grant income - Investment income 3 13,579 Other income 16,768 Total 30,347 EXPENDITURE ON Charitable activities Staff costs 16,141 Other charges 55,594 Total 71,735 Net gains on investments 45,914 NET INCOME/(EXPENDITURE) 4,526 Transfers between funds 11 (2,790) Net movement in funds 1,736 RECONCILIATION OF FUNDS Total funds brought forward 415,953 TOTAL FUNDS CARRIED FORWARD 417,689 |
d Co Restricted funds £ 1,655 - 69 (2) 1,722 - 4,804 4,804 - (3,082) 2,790 (292) 18,268 17,976 |
py 31.10.25 31.10.24 Total Total funds funds £ £ 1,655 11,573 - 7,693 13,648 15,036 16,766 14,617 32,069 48,919 16,141 16,917 60,398 55,192 76,539 72,109 45,914 44,291 1,444 21,101 - - 1,444 21,101 434,221 413,120 435,665 434,221 |
py 31.10.25 31.10.24 Total Total funds funds £ £ 1,655 11,573 - 7,693 13,648 15,036 16,766 14,617 32,069 48,919 16,141 16,917 60,398 55,192 76,539 72,109 45,914 44,291 1,444 21,101 - - 1,444 21,101 434,221 413,120 435,665 434,221 |
|---|---|---|---|
| 48,919 | |||
| 16,917 55,192 |
|||
| 72,109 | |||
| 44,291 | |||
| 21,101 - |
|||
| 21,101 413,120 |
|||
| 434,221 | |||
The notes form part of these financial statements
Page 8
The Thalidomide Society
Balance Sheet 31 October 2025
| 31.10.25 31.10.24 |
|---|
| Unrestricted Restricted Total Total |
| fund funds funds funds |
| Notes £ £ £ £ |
| CURRENT ASSETS |
| Debtors 8 5,653 - 5,653 14,749 |
| Investments 9 395,573 - 395,573 386,714 |
| Cash at bank 18,980 17,976 36,956 35,062 |
| Official Signed Copy 420,206 17,976 438,182 436,525 CREDITORS Amounts falling due within one year 10 (2,517) - (2,517) (2,304) NET CURRENT ASSETS 417,689 17,976 435,665 434,221 TOTAL ASSETS LESS CURRENT LIABILITIES 417,689 17,976 435,665 434,221 NET ASSETS 417,689 17,976 435,665 434,221 FUNDS 11 Unrestricted funds 417,689 415,953 Restricted funds 17,976 18,268 TOTAL FUNDS 435,665 434,221 The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the yea ended 31 October 2025. The members have not required the company to obtain an audit of its financial statements for the year ende 31 October 2025 in accordance with Section 476 of the Companies Act 2006. The trustees acknowledge their responsibilities for (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of th Companies Act 2006 and (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company a at the end of each financial year and of its surplus or deficit for each financial year in accordance with th requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Ac 2006 relating to financial statements, so far as applicable to the charitable company. |
The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 October 2025.
The members have not required the company to obtain an audit of its financial statements for the year ended 31 October 2025 in accordance with Section 476 of the Companies Act 2006.
-
(a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
-
(b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.
These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.
The financial statements were approved by the Board of Trustees and authorised for issue on ............................................. and were signed on its behalf by:
............................................. Mr D Mansell - Trustee
The notes form part of these financial statements
Page 9
The Thalidomide Society
Notes to the Financial Statements for the Year Ended 31 October 2025
1. GENERAL INFORMATION
The Thalidomide Society is a Charitable Incorporated Organisation (CIO). Its principal activity is to work with thalidomide and similarly impaired people, their families and supporters, providing a social network for thalidomide and similarly impaired people. Its registered office is Flat 29, Weymouth House, Hill House Mews, Bromley, BR2 0DD
Company Status
The charity is a Charitable Incorporated Organisation (CIO). It is registered on Companies House with the company number CE018092 but is not required to submit and accounts or other documents with them. The company is registered with The Charity Commission with the charity number the 231708. It is required to file an annual report with them which includes a copy of these accounts.
of the charitable company, which is a public benefit entity under FRS with the Charities SORP (FRS 102) 'Accounting and Practice applicable to charities preparing their accounts in accordance applicable in the UK and Republic of Ireland (FRS 102) (effective 1 Standard 102 'The Financial Reporting Standard applicable in the UK Act 2006. The financial statements have been prepared under as expenditure as soon as there is a legal or constructive obligation it is probable that a transfer of economic benefits will be required headings that aggregate all cost related to the category. Where costs headings they have been allocated to activities on a basis consistent
2. ACCOUNTING POLICIES
Basis of preparing the financial statements
The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.
Income
All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.
Expenditure
Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.
Taxation
The charity is exempt from corporation tax on its charitable activities.
Fund accounting
Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.
Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.
Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.
Pension costs and other post-retirement benefits
The charitable company operates a defined contribution pension scheme. Contributions payable to the charitable company's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.
Debtors
Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid.
Cash at bank and in hand
Cash at bank and in hand includes cash and short-term liquid investments with a short maturity of 3 months or less from the date of acquisition or opening of the deposit or similar account.
continued...
Page 10
The Thalidomide Society
Notes to the Financial Statements - continued for the Year Ended 31 October 2025
2. ACCOUNTING POLICIES - continued
Liabilities
Liabilities are recognised when there is an obligation at the Balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.
Liabilities are recognised at the amount that the charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.
| Official Signed Copy INVESTMENT INCOME 31.10.25 31.10.24 £ £ Investment income 13,648 15,036 NET INCOME/(EXPENDITURE) Net income/(expenditure) is stated after charging/(crediting): 31.10.25 31.10.24 £ £ Independent examiner fee 501 468 TRUSTEES' REMUNERATION AND BENEFITS There were no trustees' remuneration or other benefits for the year ended 31 October 2025 nor for the year en 31 October 2024. Trustees' expenses During the year six trustees (2024 - five) were paid expenses to cover travel costs. The amount of th payments made were £1,382 (2024 - £1,098). STAFF COSTS 31.10.25 31.10.24 £ £ Wages and salaries 15,126 13,602 Social security costs (95) - Other pension costs 1,110 1,089 16,141 14,691 |
|---|
3. INVESTMENT INCOME
4. NET INCOME/(EXPENDITURE)
5. TRUSTEES' REMUNERATION AND BENEFITS
There were no trustees' remuneration or other benefits for the year ended 31 October 2025 nor for the year ended 31 October 2024.
During the year six trustees (2024 - five) were paid expenses to cover travel costs. The amount of these payments made were £1,382 (2024 - £1,098).
6. STAFF COSTS
The average monthly number of employees during the year was as follows:
| 31.10.25 | 31.10.24 | |
|---|---|---|
| Employees | 2 | 1 |
No employees received emoluments in excess of £60,000.
continued...
Page 11
The Thalidomide Society
Notes to the Financial Statements - continued for the Year Ended 31 October 2025
| 7. | COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES | COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES | ||
|---|---|---|---|---|
| Unrestricted | Restricted | Total | ||
| fund | funds | funds | ||
| £ | £ | £ | ||
| INCOME AND ENDOWMENTS FROM | ||||
| Donations and legacies | 10,000 | 1,573 | 11,573 | |
| Charitable activities | ||||
| Grant income | - | 7,693 | 7,693 | |
| 8. | Official Signed Copy Investment income 14,935 101 Other income 14,616 1 Total 39,551 9,368 EXPENDITURE ON Charitable activities Staff costs 16,335 582 Other charges 54,266 926 Total 70,601 1,508 Net gains on investments 44,291 - NET INCOME 13,241 7,860 Transfers between funds (1,899) 1,899 Net movement in funds 11,342 9,759 RECONCILIATION OF FUNDS Total funds brought forward 404,611 8,509 TOTAL FUNDS CARRIED FORWARD 415,953 18,268 DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR 31.10.25 £ PAYE & NI debtor 59 Prepayments and accrued income 5,594 |
15,036 14,617 48,919 16,917 55,192 72,109 44,291 21,101 - 21,101 413,120 434,221 31.10.24 £ 1,183 13,566 |
||
| 5,653 | 14,749 |
continued...
Page 12
The Thalidomide Society
Notes to the Financial Statements - continued for the Year Ended 31 October 2025
9. CURRENT ASSET INVESTMENTS
| 9. | CURRENT ASSET INVESTMENTS | ||||
|---|---|---|---|---|---|
| 31.10.25 | 31.10.24 | ||||
| £ | £ | ||||
| Listed investments | 395,573 | 386,714 | |||
| 10. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE | YEAR | |||
| 31.10.25 | 31.10.24 | ||||
| £ | £ | ||||
| Pension creditor | 174 | 109 | |||
| 11. | Official Signed Copy Accruals and deferred income 2,343 2,517 MOVEMENT IN FUNDS Net Transfers At movement between 1.11.24 in funds funds £ £ £ Unrestricted funds General fund 415,953 4,526 (2,790) Restricted funds Thalidomide Society Oral History 13,617 (3,111) 2,940 Srey Hang & Beyond 4,651 29 (150) 18,268 (3,082) 2,790 TOTAL FUNDS 434,221 1,444 - Net movement in funds, included in the above are as follows: Incoming Resources Gains and resources expended losses £ £ £ Unrestricted funds General fund 30,347 (71,735) 45,914 Restricted funds Thalidomide Society Oral History 1,693 (4,804) - Srey Hang & Beyond 29 - - |
2,195 2,304 At 31.10.25 £ 417,689 13,446 4,530 17,976 435,665 Movement in funds £ 4,526 (3,111) 29 |
|||
| 1,722 | (4,804) | - | (3,082) | ||
| TOTAL FUNDS | 32,069 | (76,539) | 45,914 | 1,444 |
continued...
Page 13
The Thalidomide Society
Notes to the Financial Statements - continued for the Year Ended 31 October 2025
11. MOVEMENT IN FUNDS - continued
Comparatives for movement in funds
| Official Signed Co Net At movement 1.11.23 in funds £ £ Unrestricted funds General fund 404,611 13,241 Restricted funds Thalidomide Society Oral History 13,506 111 Srey Hang & Beyond 4,595 56 HLF (9,592) 7,693 8,509 7,860 TOTAL FUNDS 413,120 21,101 Comparative net movement in funds, included in the above are as follows: Incoming Resources resources expended £ £ Unrestricted funds General fund 39,551 (70,601) Restricted funds Thalidomide Society Oral History 1,619 (1,508) Srey Hang & Beyond 56 - HLF 7,693 - 9,368 (1,508) TOTAL FUNDS 48,919 (72,109) RELATED PARTY DISCLOSURES There were no related party transactions for the year ended 31 October 2025. |
py Transfers between At funds 31.10.24 £ £ (1,899) 415,953 - 13,617 - 4,651 1,899 - 1,899 18,268 - 434,221 Gains and Movement losses in funds £ £ 44,291 13,241 - 111 - 56 - 7,693 - 7,860 44,291 21,101 |
|---|---|
12. RELATED PARTY DISCLOSURES
Page 14
The Thalidomide Society
Detailed Statement of Financial Activities for the Year Ended 31 October 2025
| Detailed Statement of Financial Activities for the Year Ended 31 October 2025 |
||
|---|---|---|
| 31.10.25 | 31.10.24 | |
| £ | £ | |
| INCOME AND ENDOWMENTS | ||
| Donations and legacies | ||
| Donations | - | 10,000 |
| Lottery income | 1,655 | 1,573 |
| 1,655 | 11,573 | |
| Official Signed Copy Investment income Investment income 13,648 Charitable activities Grants - Other income Delgate fees 16,766 Total incoming resources 32,069 EXPENDITURE Support costs Human resources Wages 15,126 Social security (95) Pensions 1,110 Travel and subsistence costs 4,047 20,188 Other Insurance 101 Telephone and communications 556 Postage and stationery 1,021 Computer and IT expenses 737 Training seminars & workshops 43,823 Memberships and subscriptions 95 Repairs and renewals 894 Gifts 579 Website development 4,000 |
15,036 7,693 14,617 48,919 13,602 - 1,089 2,226 16,917 96 445 609 977 44,278 95 - 71 4,560 |
|
| Marketing | 1,335 | - |
| Investment fees | - | 856 |
| Accountancy fees | 1,773 | 1,662 |
| Legal fees | 936 | 1,075 |
| 55,850 | 54,724 | |
| Governance costs | ||
| Independent examiner fee | 501 | 468 |
This page does not form part of the statutory financial statements
Page 15
The Thalidomide Society
Detailed Statement of Financial Activities for the Year Ended 31 October 2025
| Detailed Statement of Financial Activities for the Year Ended 31 October 2025 |
||
|---|---|---|
| 31.10.25 | 31.10.24 | |
| £ | £ | |
| Total resources expended | 76,539 | 72,109 |
| Net expenditure before gains and losses | (44,470) | (23,190) |
| Realised recognised gains and losses | ||
| Realised gains/(losses) on fixed asset investments | 45,914 | 44,291 |
Net income |
1,444 |
21,101 |
This page does not form part of the statutory financial statements
Page 16